Taken together, we conclude that our anti-SIRPα mAbs effectively block the SIRPα-CD47 interaction, thereby enhancing the phagocytic activity induced by the anti-EGFR mAb on colorectal cancer cells. The gene discussed is EGFR; the disease is colorectal cancer.